Clinical trials: Pulmonary Hypertension
Pulmonary Arterial Hypertension
A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)
The goal of this study is to learn about the safety of sotatercept and how well Japanese children tolerate it, when taken along with standard (usual) pulmonary arterial hypertension (PAH) treatment.
- Trial name
- NCT07646860
- Testing
- Sotatercept
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Respiratory Failure (ARF), Hypertension
EIT Evaluation of Different Antihypertensive Agents on the Ventilation-Perfusion Ratio in Patients With Acute Respiratory Failure
This prospective, single-center interventional study aims to evaluate the effect of two commonly used intravenous antihypertensive agents - nicardipine and nitroglycerin - on lung ventilation-perfusion (V/Q) distribution in…
- Conditions
- Acute Respiratory Failure (ARF), Hypertension, Pulmonary Perfusion Imbalance, Aortic Dissection (Subset)
- Trial name
- NCT07603037
- Testing
- Nitroglycerin, Nicardipine
- Where
- China
- Volunteers
- 12 people
- Sponsor
- First Affiliated Hospital of Wannan Medical College
Hypertension, Diabetes
Development and Testing of a Sub-district Specific Model of 'Whole-of-government', and 'Whole-of-society' Approaches for the Prevention and Control of Non-communicable Diseases in a Sub-district of Bangladesh
Globally, non-communicable diseases (NCDs) are the leading cause of both mortality and morbidity. This intervention study aims to prevent and manage NCDs by adopting the World Health Organization's (WHO) comprehensive…
- Conditions
- Hypertension, Diabetes, Asthma, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT06453382
- Testing
- Behavioural change modification, Screening, NCD related knowledge practice and attitude
- Where
- Bangladesh
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- BRAC University
Pulmonary Arterial Hypertension
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.
- Trial name
- NCT05147805
- Testing
- Treprostinil Palmitil
- Where
- 92 sites in United States, Argentina and 15 more
- Volunteers
- 102 people
- Sponsor
- Insmed Incorporated
HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH.
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Trial name
- RENEU-PH (NCT07221513)
- Testing
- JK07
- Where
- United States
- Sponsor
- Salubris Biotherapeutics Inc
Pulmonary Arterial Hypertension
Bosentan in Children With Pulmonary Arterial Hypertension Extension Study
The main objective of the FUTURE 2 study was to assess the long-term safety and tolerability of the pediatric formulation of bosentan in children with idiopathic pulmonary arterial hypertension or familial pulmonary arterial…
- Trial name
- FUTURE 2 (NCT00319020)
- Testing
- Bosentan
- Volunteers
- 33 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
3D Imaging: Prognostic Role in Pulmonary Arterial Hypertension
Pulmonary hypertension is a rare and severe disease, affecting a young population. Survival is very poor and has been closely related to right ventricular dysfunction.
- Trial name
- HTP3S (NCT02799979)
- Testing
- 3D right ventricular imaging echocardiographic
- Where
- France
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Pulmonary Hypertension
Real World Observational Study of Sotatercept for Pulmonary Hypertension
The purpose of this study seeks to describe the real world initial experience with sotatercept in the treatment of pulmonary hypertension.
- Trial name
- NCT06751082
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Mayo Clinic
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the…
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
- Trial name
- RARE-PAH (NCT05584722)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Hypertension
Clinical Profile of Patients With Pulmonary Hypertension Due to Lung Diseases ( Single Center Experience)
Development of pulmonary hypertension (PH) in chronic lung diseases has both functional and prognostic implications . PH in Lung diseases is usually mild to moderate with preserved cardiac output, and evolves slowly alongside the…
- Trial name
- NCT02774928
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Cairo University
Persistent Severe PH After Valve Therapy
Persistent Pulmonary Artery Hypertension After Valve Replacement
Background: Persistent severe pulmonary hypertension (PH) after mechanical valve replacement is a frequent finding in patients with severe valve-diseases.
- Trial name
- SALT (NCT01238731)
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- University Hospital, Bonn
Chronic Myeloproliferative Disorders
Study of Pulmonary Hypertension in Patients With Chronic Myeloproliferative Disorders at Sohag University Hospital
Pulmonary hypertension (PH) is a complex condition that may be related to many clinical conditions. It is a serious disorder with a high morbidity and mortality rates.
- Trial name
- NCT04843475
- Testing
- Echocardiography
- Volunteers
- 150 people
- Sponsor
- Sohag University
Diabetes, Hypertension
Quality IQ Patient Simulation Physician Practice Measurement and Engagement
This study will test the quality of physician care decisions using a patient-simulation based measurement and feedback approach that combines multiple-choice care decisions with real-time, personalized scoring and feedback.
- Conditions
- Diabetes, Hypertension, Depression, Osteoarthritis
- Trial name
- Q-IQ (NCT03800901)
- Testing
- Continuing Medical Education, Quality IQ Patient Simulations
- Where
- United States
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Chronic Thromboembolic Pulmonary Hypertension
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment
Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other…
- Trial name
- SELECT (NCT03689244)
- Testing
- Selexipag
- Where
- 162 sites in United States, Argentina and 29 more
- Volunteers
- 128 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension
The goal of this clinical trial is to learn if empagliflozin works to treat patients with pulmonary arterial hypertension. It will also learn about the safety of empagliflozin.
- Trial name
- NCT06554301
- Testing
- empagliflozin in treatment pulmonary aerterial hypertension
- Where
- China
- Volunteers
- 72 people
- Sponsor
- China National Center for Cardiovascular Diseases
Pulmonary Arterial Hypertension
Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil
Acute and chronic hemodynamic dose-response and safety evaluation of LIQ861 in PAH subjects.
- Trial name
- NCT03884465
- Testing
- Inhaled dry powder treprostinil (LIQ861)
- Where
- 3 sites in France, Germany
- Volunteers
- 15 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Arterial Hypertension
A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH
PB1046-PT-CL-0005 is an open-label, dose-titration study to assess the safety, tolerability, and hemodynamic effects of individually dose-titrated PB1046 administered by weekly subcutaneous injection for 8 weeks in adult subjects…
- Trial name
- NCT03315507
- Testing
- PB1046 Subcutaneous Injection
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Pulmonary Hypertension
Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device
This study will assess the impact of sacubitril/valsartan on elevated pulmonary artery (PA) pressures in patients with heart failure (HF) with preserved ejection fraction (HFpEF), measured using a previously implanted hemodynamic…
- Trial name
- ARNIMEMS-HFpEF (NCT04753112)
- Testing
- Sacubitril / Valsartan Oral Tablet [Entresto]
- Where
- Spain
- Volunteers
- 14 people
- Sponsor
- Germans Trias i Pujol Hospital
Pulmonary Hypertension
Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide
Acute secondary pulmonary hypertension (PH) often leads to dysfunction of the right ventricle (RV) and can be a significant cause of patient morbidity and mortality.
- Trial name
- NCT02170519
- Testing
- Inhaled Iloprost
- Volunteers
- 27 people
- Sponsor
- Duke University
Interstitial Lung Disease, Pulmonary Hypertension
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
- Trial name
- PHINDER (NCT05776225)
- Testing
- Right heart catheterization (RHC)
- Where
- 42 sites in United States
- Volunteers
- 314 people
- Sponsor
- United Therapeutics